https://www.immune-onc.com/careers-posts daily 0.75 2022-03-03 https://www.immune-onc.com/pr-posts daily 0.75 2025-09-02 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-publication-of-positive-phase-1-results-for-io-202-in-cmml-and-aml-in-blood-neoplasia monthly 0.5 2025-09-02 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-first-patient-dosed-with-io-108-in-a-randomized-global-phase-1b/2-study-of-first-line-treatment-of-advanced-liver-cancer-in-clinical-collaboration-with-roche monthly 0.5 2025-09-02 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-presents-updated-data-from-phase-1b-study-of-io-202-highlighting-promising-efficacy-and-safety-data-in-cmml-patients-at-2024-american-society-of-hematology-ash-annual-meeting monthly 0.5 2025-09-02 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-positive-results-from-phase-1-dose-escalation-study-of-io-108-in-advanced-solid-tumors-published-in-the-journal-for-immunotherapy-of-cancer monthly 0.5 2025-09-02 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-to-present-additional-positive-interim-data-from-io-202-phase-1b-expansion-cohort-in-patients-with-chronic-myelomonocytic-leukemia-cmml-at-2024-eha-annual-congress monthly 0.5 2024-12-03 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-to-present-additional-positive-interim-data-from-io-202-phase-1b-expansion-cohort-in-patients-with-chronic-myelomonocytic-leukemia-cmml-at-the-2024-eha-annual-congress monthly 0.5 2024-06-14 https://www.immune-onc.com/pr-posts/immune-onc-announces-io-202-cmml-interim-data-at-eha2024 monthly 0.5 2024-05-23 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-orphan-drug-designation-granted-by-usfda-for-io-202-anti-lilrb4-for-the-treatment-of-chronic-myelomonocytic-leukemia-cmml monthly 0.5 2024-05-23 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-clinical-trial-collaboration-to-evaluate-io-108-in-a-randomized-global-phase-1b2-study-for-first-line-treatment-of-advanced-liver-cancer monthly 0.5 2024-02-20 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-to-present-phase-1-data-for-io202-at-eha-annual-meeting-2023 monthly 0.5 2023-06-08 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-to-present-encouraging-phase-1-data-for-io-108-at-aacr-annual-meeting-2023 monthly 0.5 2023-04-14 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-io-108-phase-i-clinical-trial-results-selected-for-oral-presentation-at-aacr-annual-meeting-2023 monthly 0.5 2023-03-15 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-to-showcase-leadership-in-myeloid-biology-and-drug-development-at-upcoming-scientific-and-investor-conferences monthly 0.5 2023-03-03 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-close-of-series-b-extension-financing-bringing-total-round-to-131-million monthly 0.5 2023-01-05 https://www.immune-onc.com/pr-posts/io-202-solid-tumors-tip-poster-at-sitc-press-release monthly 0.5 2022-11-10 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-appoints-two-new-members-to-its-board-of-directors monthly 0.5 2022-11-08 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-initiates-expansion-cohorts-for-io-108-and-enters-into-clinical-supply-agreement-with-regeneron monthly 0.5 2022-10-17 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-enters-into-clinical-collaboration-with-beigene-in-china monthly 0.5 2022-10-10 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-io-108-in-patients-with-advanced-solid-tumors-in-china monthly 0.5 2022-09-09 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-appointment-of-christopher-whitmore-as-chief-financial-officer-and-provides-clinical-progress-update monthly 0.5 2022-07-14 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-receives-china-investigational-new-drug-ind-approval-for-the-phase-1-study-of-io-108-a-novel-antagonist-antibody-targeting-lilrb2-ilt4-in-patients-with-solid-tumors monthly 0.5 2022-05-16 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-the-selection-of-clinical-development-candidate-io-106-a-first-in-class-myeloid-and-stromal-checkpoint-inhibitor-targeting-lair1 monthly 0.5 2022-04-20 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-to-participate-in-the-raymond-james-lilrb/ilt-symposium-on-myeloid-checkpoint-therapeutics-in-cancer monthly 0.5 2022-04-19 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-io-202-a-first-in-class-myeloid-checkpoint-inhibitor-targeting-lilrb4-in-patients-with-advanced-solid-tumors monthly 0.5 2022-04-12 https://www.immune-onc.com/pr-posts/io-108-aacr2022-data-press-release monthly 0.5 2022-04-10 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-preclinical-and-clinical-poster-presentations-for-io-108-a-novel-myeloid-checkpoint-inhibitor-targeting-lilrb2-ilt4-at-aacr-2022-annual-meeting monthly 0.5 2022-03-09 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-to-participate-in-the-cowen-42nd-annual-health-care-conference-and-the-oppenheimer-32nd-annual-healthcare-conference monthly 0.5 2022-02-28 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-receives-fda-fast-track-designation-for-io-202-the-first-anti-lilrb4-myeloid-checkpoint-inhibitor-for-the-treatment-of-relapsed-or-refractory-acute-myeloid-leukemia-aml monthly 0.5 2022-02-28 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-fda-clearance-of-ind-application-to-initiate-trial-of-io-202-a-first-in-class-myeloid-checkpoint-inhibitor-targeting-lilrb4-in-patients-with-advanced-solid-tumors monthly 0.5 2022-01-31 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-to-present-at-the-40th-annual-jp-morgan-healthcare-conference monthly 0.5 2022-01-10 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-to-present-at-evercore-isi-4th-annual-healthconx-conference monthly 0.5 2021-11-22 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-to-present-data-supporting-therapeutic-potential-of-lair1-antagonist-antibodies-at-the-society-for-immunotherapy-of-cancer-sitc-36th-annual-meeting monthly 0.5 2021-11-09 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-io-108-a-novel-antagonist-antibody-targeting-lilrb2-ilt4-in-patients-with-advanced-solid-tumors monthly 0.5 2021-10-13 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-fda-clearance-of-ind-application-to-initiate-first-in-human-trial-of-io-108-a-novel-antagonist-antibody-targeting-lilrb2-in-patients-with-advanced-solid-tumors monthly 0.5 2021-08-12 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-expands-global-footprint-and-appoints-maggie-gu-as-china-general-manager monthly 0.5 2021-08-12 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-appoints-stuart-lutzker-md-phd-to-scientific-advisory-board monthly 0.5 2021-08-12 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-first-public-presentation-of-data-for-its-myeloid-checkpoint-inhibitor-io-202-in-solid-tumors-at-aacr21 monthly 0.5 2021-08-12 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-73-million-in-series-b1-and-b2-financing-to-advance-its-portfolio-of-novel-immunotherapies-in-blood-cancers-and-solid-tumors monthly 0.5 2021-07-09 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-orphan-drug-designation-of-io-202-anti-lilrb4-for-treatment-of-aml-and-poster-presentation-at-ash-2020 monthly 0.5 2021-07-09 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-to-present-preclinical-data-for-io-108-a-novel-antagonist-antibody-targeting-lilrb2-ilt4-in-solid-tumors-at-sitc-2020 monthly 0.5 2021-07-09 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-sitc-poster-presentation-on-io-108-a-novel-cancer-immunotherapy-targeting-lilrb2-ilt4-for-solid-tumors monthly 0.5 2021-07-09 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-first-patient-dosed-in-phase-i-trial-evaluating-io-202-a-first-in-class-antibody-for-the-treatment-of-acute-myeloid-leukemia monthly 0.5 2021-07-09 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-awarded-214-million-national-cancer-institute-sbir-grant-to-support-development-of-io-202-a-first-in-class-antibody-targeting-lilrb4 monthly 0.5 2021-07-09 https://www.immune-onc.com/pr-posts/acute-myeloid-leukemia-background-for-media monthly 0.5 2021-07-09 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-ind-application-for-first-in-human-trial-of-io-202-a-novel-antibody-for-the-treatment-of-acute-myeloid-leukemia-receives-fda-clearance monthly 0.5 2021-07-09 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-prepares-for-its-next-phase-of-growth-with-new-leadership-appointments-and-key-board-member-additions monthly 0.5 2021-07-09 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-and-university-of-texas-report-a-novel-target-for-acute-myeloid-leukemia-in-nature monthly 0.5 2021-07-09 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-key-executive-appointments-and-series-b-funding monthly 0.5 2021-07-09 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-inc-awarded-buzz-of-bio monthly 0.5 2021-07-09 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-inc-selected-to-join-the-prestigious-stanford-backed-startx-community monthly 0.5 2021-07-09 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-inc-announces-partnership-with-university-of-texas-to-develop-novel-cancer-immunotherapy monthly 0.5 2021-07-09 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-inc-announces-licensing-and-collaboration-with-albert-einstein-college-of-medicine-and-memorial-sloan-kettering-cancer-center-to-develop-novel-cancer-immunotherapy monthly 0.5 2021-07-09 https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-inc-announces-7-million-series-a-financing monthly 0.5 2021-07-09 https://www.immune-onc.com/pr-posts/category/news monthly 0.5 https://www.immune-onc.com/pr-posts/category/press+releases monthly 0.5 https://www.immune-onc.com/pr-posts/category/events monthly 0.5 https://www.immune-onc.com/publications-abstracts daily 0.75 2025-09-02 https://www.immune-onc.com/publications-abstracts/oral-presentationio-202-a-novel-anti-lilrb4-antibody-with-azacitidine-for-hypomethylating-agent-naive-chronic-myelomonocytic-leukemia-phase-1b-expansion-cohort-results-ykl4g monthly 0.5 2025-09-02 https://www.immune-onc.com/publications-abstracts/oral-presentationio-202-a-novel-anti-lilrb4-antibody-with-azacitidine-for-hypomethylating-agent-naive-chronic-myelomonocytic-leukemia-phase-1b-expansion-cohort-results monthly 0.5 2024-12-10 https://www.immune-onc.com/publications-abstracts/4uxchczb7sw9mnv6nrhozef3ufwt44-xz67n-t8y6w-3njj2 monthly 0.5 2024-12-10 https://www.immune-onc.com/publications-abstracts/4uxchczb7sw9mnv6nrhozef3ufwt44-xz67n-t8y6w monthly 0.5 2024-06-14 https://www.immune-onc.com/publications-abstracts/4uxchczb7sw9mnv6nrhozef3ufwt44 monthly 0.5 2023-06-18 https://www.immune-onc.com/publications-abstracts/io-312-aacr-2023-presentation-lb217 monthly 0.5 2023-04-19 https://www.immune-onc.com/publications-abstracts/io-108-aacr-2023-presentation-ct040 monthly 0.5 2023-04-19 https://www.immune-onc.com/publications-abstracts/sitc-2022 monthly 0.5 2022-12-01 https://www.immune-onc.com/publications-abstracts/sitc-2022-workshop-poster monthly 0.5 2022-04-29 https://www.immune-onc.com/publications-abstracts/a-first-in-human-phase-1-trial-of-io-108 monthly 0.5 2022-04-13 https://www.immune-onc.com/publications-abstracts/aacr-2022 monthly 0.5 2022-04-12 https://www.immune-onc.com/publications-abstracts/sitc-2022-workshop-poster-3ncwy-7jekt monthly 0.5 2022-05-19 https://www.immune-onc.com/publications-abstracts/sitc-2022-workshop-poster-3ncwy-ts8yd monthly 0.5 2022-05-19 https://www.immune-onc.com/publications-abstracts/antagonistic-antibodies-targeting-lair1-enhance-t-lymphocyte-activation-and-promote-inflammatory-phenotypes-in-myeloid-cells monthly 0.5 2022-08-19 https://www.immune-onc.com/publications-abstracts/io-202-a-first-in-class-lilrb4-antagonist-antibody monthly 0.5 2022-08-18 https://www.immune-onc.com/publications-abstracts/leukocyte-immunoglobulin-like-receptor-subfamily-b-therapeutic-targets-in-cancer monthly 0.5 2021-07-22 https://www.immune-onc.com/publications-abstracts/a-first-in-human-phase-1-study-of-the-anti-lilrb4-antibody-io-202 monthly 0.5 2022-08-20 https://www.immune-onc.com/publications-abstracts/preclinical-characterization-of-a-novel-therapeutic-antibody-targeting-lilrb2 monthly 0.5 2022-08-20 https://www.immune-onc.com/publications-abstracts/sitc-2022-workshop-poster-3ncwy-4drz3 monthly 0.5 2022-05-19 https://www.immune-onc.com/publications-abstracts/antagonist-antibodies-targeting-lair1-promote-inflammatory-phenotype-in-myeloid-cells-and-activate-lymphocytes monthly 0.5 2022-08-20 https://www.immune-onc.com/publications-abstracts/sitc-2022-workshop-poster-3ncwy-z3xn2 monthly 0.5 2022-05-19 https://www.immune-onc.com/publications-abstracts/leukocyte-immunoglobulin-like-receptor-b1-and-b4-lilrb1-and-lilrb4 monthly 0.5 2021-07-22 https://www.immune-onc.com/publications-abstracts/lilrb4-targeting-antibody-drug-conjugates-for-the-treatment-of-acute-myeloid-leukemia monthly 0.5 2021-07-22 https://www.immune-onc.com/publications-abstracts/antagonistic-anti-lilrb1-monoclonal-antibody-regulates-antitumor-functions-of-natural-killer-cells monthly 0.5 2021-07-22 https://www.immune-onc.com/publications-abstracts/sitc-2022-workshop-poster-3ncwy-y94bt monthly 0.5 2022-05-19 https://www.immune-onc.com/publications-abstracts/disrupting-lilrb4-apoe-interaction-by-an-efficacious-humanized-antibody-reverses-t-cell-suppression-and-blocks-aml-development monthly 0.5 2021-07-22 https://www.immune-onc.com/publications-abstracts/targeting-the-immune-inhibitory-receptor-lilrb4-to-treat-acute-myeloid-leukemia-aml monthly 0.5 2022-08-20 https://www.immune-onc.com/publications-abstracts/lilrb4-signalling-in-leukaemia-cells-mediates-t-cell-suppression-and-tumour-infiltration monthly 0.5 2021-07-21 https://www.immune-onc.com/publications-abstracts/sitc-2022-workshop-poster-3ncwy-pf2fp-2szj2 monthly 0.5 2022-05-19 https://www.immune-onc.com/publications-abstracts/sitc-2022-workshop-poster-3ncwy-f4me7 monthly 0.5 2022-05-19 https://www.immune-onc.com/publications-abstracts/sitc-2022-workshop-poster-3ncwy-lzpxj monthly 0.5 2022-05-19 https://www.immune-onc.com/publications-abstracts/sitc-2022-workshop-poster-3ncwy-pf2fp monthly 0.5 2022-05-19 https://www.immune-onc.com/publications-abstracts/sitc-2022-workshop-poster-3ncwy monthly 0.5 2022-05-18 https://www.immune-onc.com/news-1 daily 0.75 2024-12-15 https://www.immune-onc.com/news-1/io-202-receives-fda-orphan-drug-designation-for-cmml-ehml8 monthly 0.5 2024-12-15 https://www.immune-onc.com/news-1/jm8zd02aij2526eowaqc8t44c710gj-z56n7-a55ca-7fwkw-hz9zy-yn5yt monthly 0.5 2024-12-15 https://www.immune-onc.com/news-1/jm8zd02aij2526eowaqc8t44c710gj-z56n7-a55ca-7fwkw-hz9zy monthly 0.5 2024-12-15 https://www.immune-onc.com/news-1/jm8zd02aij2526eowaqc8t44c710gj-z56n7-a55ca-7fwkw monthly 0.5 2024-03-18 https://www.immune-onc.com/news-1/io-202-receives-fda-orphan-drug-designation-for-cmml monthly 0.5 2024-03-11 https://www.immune-onc.com/news-1/mhdnd0pooms61g8cui2q3m8g2cby1x-nhbsn monthly 0.5 2024-02-02 https://www.immune-onc.com/news-1/going-head-to-head-with-merck-on-io-genentech-vets-raise-fresh-round-and-enter-clinic-8ffx4-c72tn-f9y9n-c9m5n monthly 0.5 2023-06-16 https://www.immune-onc.com/news-1/dr-taylor-on-preliminary-efficacy-and-safety-data-for-io-108-in-advanced-solid-tumors monthly 0.5 2024-03-11 https://www.immune-onc.com/news-1/going-head-to-head-with-merck-on-io-genentech-vets-raise-fresh-round-and-enter-clinic-8ffx4-c72tn-f9y9n monthly 0.5 2023-06-15 https://www.immune-onc.com/news-1/going-head-to-head-with-merck-on-io-genentech-vets-raise-fresh-round-and-enter-clinic-8ffx4-c72tn monthly 0.5 2023-04-21 https://www.immune-onc.com/news-1/jm8zd02aij2526eowaqc8t44c710gj-z56n7-a55ca monthly 0.5 2023-07-13 https://www.immune-onc.com/news-1/going-head-to-head-with-merck-on-io-genentech-vets-raise-fresh-round-and-enter-clinic-8ffx4-e662e monthly 0.5 2022-11-22 https://www.immune-onc.com/news-1/going-head-to-head-with-merck-on-io-genentech-vets-raise-fresh-round-and-enter-clinic-8ffx4 monthly 0.5 2022-11-22 https://www.immune-onc.com/news-1/jm8zd02aij2526eowaqc8t44c710gj-z56n7 monthly 0.5 2022-03-08 https://www.immune-onc.com/news-1/jm8zd02aij2526eowaqc8t44c710gj monthly 0.5 2023-07-13 https://www.immune-onc.com/news-1/cxnn63d79xy0nxnfhxtxt2y4gr3vzm monthly 0.5 2022-02-25 https://www.immune-onc.com/news-1/mhdnd0pooms61g8cui2q3m8g2cby1x monthly 0.5 2021-08-10 https://www.immune-onc.com/news-1/immune-onc-ratchets-up-a-series-b1-and-b2-for-73m monthly 0.5 2021-07-22 https://www.immune-onc.com/news-1/going-head-to-head-with-merck-on-io-genentech-vets-raise-fresh-round-and-enter-clinic monthly 0.5 2022-11-17 https://www.immune-onc.com/news-1/immune-onc-building-broad-pipeline-of-myeloid-checkpoint-inhibitors monthly 0.5 2021-07-22 https://www.immune-onc.com/news-1/eastwest-ceo-developments-in-the-oncology-landscape monthly 0.5 2021-07-22 https://www.immune-onc.com/news-1/researchers-find-potential-new-way-to-target-lethal-form-of-leukemia monthly 0.5 2021-07-22 https://www.immune-onc.com/news-1/two-genentech-vets-reunite-at-immune-onc-to-help-steer-its-33m-drive-to-the-clinic monthly 0.5 2021-07-22 https://www.immune-onc.com/news-1/what-you-need-to-know-about-immune-onc-therapeutics monthly 0.5 2021-07-22 https://www.immune-onc.com/news-1/top-20-life-science-startups-to-watch-in-2018 monthly 0.5 2021-07-22 https://www.immune-onc.com/news-1/category/news monthly 0.5 https://www.immune-onc.com/news-1/category/events monthly 0.5 https://www.immune-onc.com/home daily 1.0 2025-01-23 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/1627349102664-2U80E2J1EC3UMD78FKJE/pexels-matt-hardy-3560168_Edit.jpg Home - Turning the Tide on Immune Regulation Immunotherapy, which harnesses the body’s own immune system to fight against disease, has changed the way we think about treatment — and even cures. Recent breakthroughs in our understanding of the role of myeloid cells may yield entirely novel therapies that can further unlock the immune system’s ability to defeat certain cancers and autoimmune diseases. https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/1627349023105-TWNPSS7SYLMMY1RX6Z96/pexels-arthouse-studio-4646078_Edit.jpg Home - Translating Scientific Discoveries Into Breakthrough Treatments In recent years, T-cell checkpoint inhibitors such as anti-PD-(L)1 have emerged as the standard-of-care for the treatment of multiple solid tumor cancers. While this progress is encouraging, to date, these therapies have only been effective in a subset of patients. Currently, 70-80 percent of cancer patients with solid tumors do not achieve durable responses to T-cell checkpoint therapies, and people with many types of blood cancers, including acute myeloid leukemia (AML), have yet to benefit from the promise of immunotherapy. https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/1628126669448-Z3XC0F2SR9DU87WE4RI2/LogoRow_2021-08-04.png Home - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.immune-onc.com/publications-and-abstracts daily 0.75 2022-05-18 https://www.immune-onc.com/news daily 0.75 2024-09-16 https://www.immune-onc.com/io106 daily 0.75 2022-07-13 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/1625070981061-2HSFIYQ3DZE2Y8BU6MFV/IO-106%2B%28Anti-LAIR1%29%2BMOAs.png IO-106 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.immune-onc.com/team daily 0.75 2025-09-16 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/1644600609985-VTVAPUWGY1KJL6CCSW9Y/IMG_3184+%281%29.JPG Team - Hong Xiang, PhD Chief Development Officer Hong joined Immune-Onc in Jan 2022 as SVP, Head of Development Sciences, and an Executive Committee (EC) member. She has demonstrated strategic leadership of our business and scientific leadership of our first-in-class pipeline. Hong has over 25 years of experience in all phases of drug development at both established and early-stage biotech companies. Prior to Immune-Onc, Hong was a functional area lead at Amgen and clinical pharmacology lead for bemarituzumab, a fast-track Phase 3 program in gastric and gastroesophageal junction cancer with multiple clinical studies in different combinations or in other tumor types. Full Bio LinkedIn https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/1625073337178-FB3W2UR1O0MTHQLAFDER/Charlene_Liao.jpeg Team - Charlene Liao, PhD Founder, CEO and Chair of the Board Charlene has 25 years of industry experience in drug development and business leadership. From 2002-2016, Charlene held global drug development roles at Genentech where she was instrumental in leading development efforts across the product lifecycle for ten new molecular entities (NMEs) in a variety of therapeutic areas. Full Bio LinkedIn https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/07c77fc7-adb1-4722-a87c-a23b199270c0/Barb+Klencke+-+WebRes.jpg Team - Barbara Klencke, MD Chief Medical Advisor Dr. Klencke is a world-class drug developer and research & development expert, having made significant contributions to the oncology community with the development and approval of several first-in-class therapies. Since 2015, she has served as the chief medical officer of Sierra Oncology Inc., a publicly traded clinical-stage biopharmaceutical company recently acquired by GSK in 2022. From 2011 to 2015, Barbara served as senior vice president of global development at Onyx Pharmaceuticals, acquired by Amgen Inc. in 2013. She also led a variety of both early- and late-stage oncology programs while at Genentech, Inc. from 2003 to 2011. Full Bio LinkedIn https://www.immune-onc.com/for-patients daily 0.75 2025-01-22 https://www.immune-onc.com/maggie-gu daily 0.75 2021-07-09 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/8cae9192-4492-41de-90d5-d57e82f0f8a3/Maggie_Gu.jpeg Maggie Gu - Maggie Gu Tobias Keene, D.D.S. Hailing from Richmond, Virginia, Dr. Tobias Keene brings a bit of unabashed Southern hospitality to all his patients. He moved to Washington, D.C. over thirty years ago as a freshman at Ivy College. Right after graduation, he attended World University’s School of Dentistry. Before opening Keene Dental in 1994, he worked for free clinics and some of the finest practices in the District. He is part of the 123 Dental Association and stays up-to-date on the latest dental discoveries. When not striving to keep his patients happy and healthy, he’s enjoys hiking with his family in Rock Creek Park. https://www.immune-onc.com/careers daily 0.75 2024-02-09 https://www.immune-onc.com/hong-xiang daily 0.75 2023-09-05 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/1644600609985-VTVAPUWGY1KJL6CCSW9Y/IMG_3184+%281%29.JPG Hong Xiang - Hong Xiang, PhD Tobias Keene, D.D.S. Hailing from Richmond, Virginia, Dr. Tobias Keene brings a bit of unabashed Southern hospitality to all his patients. He moved to Washington, D.C. over thirty years ago as a freshman at Ivy College. Right after graduation, he attended World University’s School of Dentistry. Before opening Keene Dental in 1994, he worked for free clinics and some of the finest practices in the District. He is part of the 123 Dental Association and stays up-to-date on the latest dental discoveries. When not striving to keep his patients happy and healthy, he’s enjoys hiking with his family in Rock Creek Park. https://www.immune-onc.com/charlene-liao daily 0.75 2022-11-07 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/1625073337178-FB3W2UR1O0MTHQLAFDER/Charlene_Liao.jpeg Charlene Liao - Charlene Liao, PhD Tobias Keene, D.D.S. Hailing from Richmond, Virginia, Dr. Tobias Keene brings a bit of unabashed Southern hospitality to all his patients. He moved to Washington, D.C. over thirty years ago as a freshman at Ivy College. Right after graduation, he attended World University’s School of Dentistry. Before opening Keene Dental in 1994, he worked for free clinics and some of the finest practices in the District. He is part of the 123 Dental Association and stays up-to-date on the latest dental discoveries. When not striving to keep his patients happy and healthy, he’s enjoys hiking with his family in Rock Creek Park. https://www.immune-onc.com/guoliang-yu daily 0.75 2021-07-09 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/1625764966224-1VO9RFPSDUYSL02W3O5U/guo_liang.jpeg Guo-Liang Yu - Guo-Liang Yu, PhD Tobias Keene, D.D.S. Hailing from Richmond, Virginia, Dr. Tobias Keene brings a bit of unabashed Southern hospitality to all his patients. He moved to Washington, D.C. over thirty years ago as a freshman at Ivy College. Right after graduation, he attended World University’s School of Dentistry. Before opening Keene Dental in 1994, he worked for free clinics and some of the finest practices in the District. He is part of the 123 Dental Association and stays up-to-date on the latest dental discoveries. When not striving to keep his patients happy and healthy, he’s enjoys hiking with his family in Rock Creek Park. https://www.immune-onc.com/press-releases daily 0.75 2021-07-22 https://www.immune-onc.com/expanded-access-policy daily 0.75 2022-02-25 https://www.immune-onc.com/christopher-whitmore daily 0.75 2022-07-13 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/420943cc-2a94-4e1a-b9d0-3aabab6cac54/ChristopherWhitmore.jpg Christopher Whitmore - Chris Whitmore, CPA Tobias Keene, D.D.S. Hailing from Richmond, Virginia, Dr. Tobias Keene brings a bit of unabashed Southern hospitality to all his patients. He moved to Washington, D.C. over thirty years ago as a freshman at Ivy College. Right after graduation, he attended World University’s School of Dentistry. Before opening Keene Dental in 1994, he worked for free clinics and some of the finest practices in the District. He is part of the 123 Dental Association and stays up-to-date on the latest dental discoveries. When not striving to keep his patients happy and healthy, he’s enjoys hiking with his family in Rock Creek Park. https://www.immune-onc.com/jack-donahue daily 0.75 2022-11-17 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/1f414460-4248-4fac-b0ad-fea19a851e61/JackDonahue.jpg Jack Donahue - Jack Donahue Board Member Jack Donahue is the Founding Managing Partner at Donahue Consulting Group (DCG), a boutique consulting firm providing advisory services to early and mid-stage tech and biotech companies in the US and Hong Kong. Additionally, Jack serves as an advisor to Advantech Capital and a non-Executive Director at Northern Light Venture Capital. Prior to founding DCG, Jack held operational management position at CLSA in Hong Kong, and was a consultant at Systems Evolution Inc. (SEI) where he consulted for global finance and consumer products clients. Prior to consulting Jack worked for a systems integrator serving the US Department of Defense with a program geographical focus in Europe and the Middle East. He started his professional career in Commercial Real Estate Finance in both New York and Boston. Jack received his BA in economics from Harvard University and serves as a director or board observer for early-stage companies and non-profit organizations. https://www.immune-onc.com/austin-l-gurney daily 0.75 2022-11-07 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/68dfecbc-349b-40bd-9ad9-fa8847e8e3f2/Austin+Gurney.jpg Austin L. Gurney - Austin L. Gurney, Ph.D. Tobias Keene, D.D.S. Hailing from Richmond, Virginia, Dr. Tobias Keene brings a bit of unabashed Southern hospitality to all his patients. He moved to Washington, D.C. over thirty years ago as a freshman at Ivy College. Right after graduation, he attended World University’s School of Dentistry. Before opening Keene Dental in 1994, he worked for free clinics and some of the finest practices in the District. He is part of the 123 Dental Association and stays up-to-date on the latest dental discoveries. When not striving to keep his patients happy and healthy, he’s enjoys hiking with his family in Rock Creek Park. https://www.immune-onc.com/liqun-luo daily 0.75 2022-10-28 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/bb12eed6-7b44-42c4-9ca9-9ee3f1371652/Liqun+Luo.jpg Liqun Luo - Liqun Luo, Ph.D. Tobias Keene, D.D.S. Hailing from Richmond, Virginia, Dr. Tobias Keene brings a bit of unabashed Southern hospitality to all his patients. He moved to Washington, D.C. over thirty years ago as a freshman at Ivy College. Right after graduation, he attended World University’s School of Dentistry. Before opening Keene Dental in 1994, he worked for free clinics and some of the finest practices in the District. He is part of the 123 Dental Association and stays up-to-date on the latest dental discoveries. When not striving to keep his patients happy and healthy, he’s enjoys hiking with his family in Rock Creek Park. https://www.immune-onc.com/dave-chenn daily 0.75 2022-10-28 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/7288b022-8936-48b8-b65f-22786ca5bdca/Dave+Chenn+photo.jpg Dave Chenn - Dave Chenn, M.B.A. Tobias Keene, D.D.S. Hailing from Richmond, Virginia, Dr. Tobias Keene brings a bit of unabashed Southern hospitality to all his patients. He moved to Washington, D.C. over thirty years ago as a freshman at Ivy College. Right after graduation, he attended World University’s School of Dentistry. Before opening Keene Dental in 1994, he worked for free clinics and some of the finest practices in the District. He is part of the 123 Dental Association and stays up-to-date on the latest dental discoveries. When not striving to keep his patients happy and healthy, he’s enjoys hiking with his family in Rock Creek Park. https://www.immune-onc.com/bing-yao daily 0.75 2022-11-07 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/2968f9a3-6a57-422a-8aac-07ea7958030b/unnamed.jpg Bing Yao - Bing Yao, Ph.D. Tobias Keene, D.D.S. Hailing from Richmond, Virginia, Dr. Tobias Keene brings a bit of unabashed Southern hospitality to all his patients. He moved to Washington, D.C. over thirty years ago as a freshman at Ivy College. Right after graduation, he attended World University’s School of Dentistry. Before opening Keene Dental in 1994, he worked for free clinics and some of the finest practices in the District. He is part of the 123 Dental Association and stays up-to-date on the latest dental discoveries. When not striving to keep his patients happy and healthy, he’s enjoys hiking with his family in Rock Creek Park. https://www.immune-onc.com/barbara-j-klencke daily 0.75 2025-09-16 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/89fe894e-ea25-4e5b-b409-a8503cb7e1c4/Barb+Klencke+-+WebRes.jpg Barbara J. Klencke - Barbara J. Klencke, M.D. Tobias Keene, D.D.S. Hailing from Richmond, Virginia, Dr. Tobias Keene brings a bit of unabashed Southern hospitality to all his patients. He moved to Washington, D.C. over thirty years ago as a freshman at Ivy College. Right after graduation, he attended World University’s School of Dentistry. Before opening Keene Dental in 1994, he worked for free clinics and some of the finest practices in the District. He is part of the 123 Dental Association and stays up-to-date on the latest dental discoveries. When not striving to keep his patients happy and healthy, he’s enjoys hiking with his family in Rock Creek Park. https://www.immune-onc.com/fiona-yu daily 0.75 2024-03-20 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/1393298f-2893-4b59-a653-bdc9ecb5825d/Fiona-Yu.jpg Fiona Yu - Fiona Yu, M.B.A. Tobias Keene, D.D.S. Hailing from Richmond, Virginia, Dr. Tobias Keene brings a bit of unabashed Southern hospitality to all his patients. He moved to Washington, D.C. over thirty years ago as a freshman at Ivy College. Right after graduation, he attended World University’s School of Dentistry. Before opening Keene Dental in 1994, he worked for free clinics and some of the finest practices in the District. He is part of the 123 Dental Association and stays up-to-date on the latest dental discoveries. When not striving to keep his patients happy and healthy, he’s enjoys hiking with his family in Rock Creek Park. https://www.immune-onc.com/io-202 daily 0.75 2023-04-18 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/1625070357975-TYISMVWAS090NOC30IBV/IO-202%2B%28Anti-LILRB4%29%2BMOAs%2Bin%2BHematologic%2BMalignancies.png IO-202 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/765319b3-d337-416d-a029-c293415ac46a/Pipeline_IO-202v2_04-15-2023.png IO-202 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.immune-onc.com/io108 daily 0.75 2023-04-18 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/1625070756837-TXNDRLGE4GL3KZXUK0Q0/IO-108%2B%28Anti-LILRB2%29%2BMOAs.png IO-108 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.immune-onc.com/pipeline-old daily 0.75 2024-02-20 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/1628123942449-T678516G0PQYGSJNTTKB/CD163-40X-Lung-Cancer.jpg Pipeline Overview - The Role of Myeloid Cells in Cancer Myeloid cells are abundant and often immune suppressive in the tumor microenvironment (TME). For example, in many types of solid tumors the main tumor-infiltrating immune cell population is monocyte-derived macrophages. Myeloid cells modulate key cancer-associated activities and could affect virtually all types of cancer therapy. Initially intrinsic mutations drive cells to malignancy. Non-cancerous cells, including myeloid cells, come to the scene as if initiating a wound-healing process. In the TME, they are influenced by cancer cells and often support tumor growth, metastasis and immune evasion. Image: Staining of macrophage (CD163) in lung cancer at 40x https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/1625069576091-NZPIKF372VB7Q7D0IXQA/LILRB%2BFamily.png Pipeline Overview - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/b0812250-6a7f-4356-a206-c769ce07899e/Pipeline_Updated04-15-2023.png Pipeline Overview - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.immune-onc.com/pipeline daily 0.75 2025-02-19 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/826c8dc5-cb51-42be-a0b0-c1a92950a672/1024px-CMML.jpg Pipeline Overview - The Role of Myeloid Cells in Cancer and Autoimmune Disease Myeloid cells are abundant and have crucial regulatory functions in a broad range of conditions ranging from cancer to autoimmune diseases. Dysregulation of these myeloid cells causes either suppressed or enhanced immune responses, leading to cancers or autoimmune diseases, respectively. Image: MDS UK Patient Support Group https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/d5f918d1-99a9-4256-80a4-dc67bfbbc480/LILRB%2BFamily.jpg Pipeline Overview - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/c0af3f65-020a-4e83-8883-591337a5d148/PipelineOverview_BloodCancer%402x.png https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/ce884a6a-4fd7-4a19-a903-eec1f21a1022/PipelineOverview_Immunology%26Inflammation%402x.png https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/f479e659-f5aa-40e8-9b53-5c2de5b24664/PipelineOverview_SolidTumors%402x.png https://www.immune-onc.com/immunology-inflammation daily 0.75 2025-01-22 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/ce884a6a-4fd7-4a19-a903-eec1f21a1022/PipelineOverview_Immunology%26Inflammation%402x.png https://www.immune-onc.com/solid-tumors daily 0.75 2024-06-14 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/f479e659-f5aa-40e8-9b53-5c2de5b24664/PipelineOverview_SolidTumors%402x.png https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/10cb8031-c91d-463f-8ac1-0990f6e19e3d/IO-108%2B%28Anti-LILRB2%29%2BMOAs.jpg https://www.immune-onc.com/blood-cancers daily 0.75 2025-05-12 https://images.squarespace-cdn.com/content/v1/60dc8b9325bba74a54bb572f/c0af3f65-020a-4e83-8883-591337a5d148/PipelineOverview_BloodCancer%402x.png